Teleflex’s UroLift System shows positive results in two BPH trails

Teleflex (TFX) announced the presentation of new clinical data at the 2025 American Urological Association Annual Meeting in Las Vegas April 26-29. Data from two randomized controlled trials reinforce the UroLift System’s advantages compared with Rezm and tamsulosin, particularly in terms of early patient satisfaction, rapid symptom relief, and sexual function outcomes. Research presentations outlined the key findings from the studies: results from the CLEAR RCT suggest factors corresponding to early patient satisfaction are better following UroLift PUL vs. Rezum WVTT1; mMen treated with the UroLift System were significantly more satisfied with their results at two weeks and at one month after treatment. Those who received the UroLift System procedure also had shorter catheterization times, better symptom relief, and better sexual function outcomes during the early recovery period compared to Rezm patients.UroLift PUL demonstrates significantly better efficacy and patient experience outcomes vs. Tamsulosin. At three months, men who were treated with the UroLift System showed significantly better symptom improvement compared to those who took medication. UroLift System patients reported better sexual function outcomes and overall experience. Low risk of rectal wall infiltration and reversibility.